Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition PR Newswire GERMANTOWN, Md., June 16, 2017 GERMANTOWN, Md., June 16, 2017 /PRNewswire/...
Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of GenVec, Inc. - GNVC PR Newswire NEW YORK, April 23, 2017 NEW YORK, April 23, 2017 /PRNewswire/ -- Juan...
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results - Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $44.1 million including non-cash charges...
WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders PR Newswire NEW YORK, Feb. 8, 2017 NEW YORK, Feb. 8, 2017 /PRNewswire/ -- WeissLaw LLP is...
Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec's AdenoVerse™ to be Integrated into Intrexon's Proprietary Synthetic Biology Platform PR Newswire GERMANTOWN...
GenVec to Present at Phacilitate Cell & Gene Therapy World 2017 PR Newswire GAITHERSBURG, Md., Jan. 11, 2017 GAITHERSBURG, Md., Jan. 11, 2017 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a...
GenVec Effects 1-for-10 Reverse Stock Split PR Newswire GAITHERSBURG, Md., Dec. 1, 2016 GAITHERSBURG, Md., Dec. 1, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) ("GenVec" or "the Company...
GenVec Reports Third Quarter 2016 Financial Results PR Newswire GAITHERSBURG, Md., Nov. 4, 2016 GAITHERSBURG, Md., Nov. 4, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported...
GenVec To Present At 2016 Cell & Gene Meeting On The Mesa Wednesday, October 5th, 11 a.m. PDT/2:00 pm EDT PR Newswire GAITHERSBURG, Md., Sept. 28, 2016 GAITHERSBURG, Md., Sept. 28, 2016...
GenVec Reports Second Quarter 2016 Financial Results PR Newswire GAITHERSBURG, Md., Aug. 5, 2016 GAITHERSBURG, Md., Aug. 5, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today reported...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.